Plasma Derived Therapy Market: Market Expansion and Future Outlook (2034)

The plasma derived therapy market has emerged as a vital component of modern healthcare, addressing complex diseases through biologically potent treatments extracted from human plasma. As chronic conditions and immune-related disorders continue to rise, the demand for plasma-based therapies has surged globally. In 2024, the global plasma derived therapy market size was valued at USD 24.00 billion, and it is poised to grow at a CAGR of 6.90% from 2025 to 2034, reaching approximately USD 46.77 billion by the end of the forecast period.

Get a free sample report: https://tinyurl.com/2zurpf9a

This article offers a deep dive into the market dynamics, trends, competitive landscape, and the key growth factors fueling this important segment of biopharmaceuticals.

Overview of Plasma Derived Therapy Market

Plasma-derived therapies are biologics created by extracting therapeutic proteins from human plasma, including immunoglobulins, clotting factors, and albumin. These therapies are crucial for treating a wide range of life-threatening, rare, and chronic conditions such as primary immunodeficiency disorders, hemophilia, and autoimmune diseases.

Plasma-based products are different from synthetic biologics in that they originate from donated human plasma and undergo rigorous processing and viral inactivation. The importance of these therapies continues to grow as global healthcare systems emphasize advanced treatment options and as plasma donation infrastructure expands.

Plasma Derived Therapy Market Size and Share

The plasma derived therapy market size reached USD 24.00 billion in 2024, underpinned by rising demand for advanced biologics, expansion of plasma collection networks, and increasing patient awareness.

By 2034, the market is expected to reach a size of USD 46.77 billion, reflecting a CAGR of 6.90% over the forecast period.

Regional Share Insights

North America leads the market, driven by advanced healthcare infrastructure, strong reimbursement policies, and a high prevalence of rare disorders.

Europe follows closely, with countries such as Germany, France, and the UK emphasizing innovation and accessibility in plasma-based therapies.

Asia-Pacific is witnessing fast growth due to rising healthcare investments, improved access to care, and increasing awareness about immunodeficiencies and bleeding disorders.

Market Dynamics and Emerging Trends

Key Drivers

Increasing access to healthcare: Expanding healthcare infrastructure and insurance coverage in developing countries have enabled broader patient access to plasma therapies.

Rising prevalence of immunodeficiency and bleeding disorders: As diagnostic capabilities improve, more patients are identified and treated with plasma-derived products.

Technological advancements: Innovations in fractionation, purification, and viral inactivation technologies are enhancing the quality and safety of plasma therapies.

Expanded plasma collection initiatives: Governments and private players are investing in large-scale plasma donation centers to meet growing demand.

Read full report with table of content: https://tinyurl.com/mwaw7x54

Market Restraints

Limited plasma supply: Despite high demand, plasma collection remains a complex and time-consuming process.

High manufacturing costs: The plasma fractionation process is costly and regulated, often translating into higher product prices.

Stringent regulatory requirements: Plasma-derived therapies are subject to strict guidelines, especially regarding donor safety and viral inactivation.

Trends Transforming the Market

Emergence of recombinant alternatives: While plasma-derived therapies remain dominant, recombinant analogs are gaining traction, especially in developed markets.

Outsourcing of plasma fractionation: Smaller companies are outsourcing production to contract manufacturing organizations (CMOs) to reduce operational burden.

Integration of AI and analytics: AI is being used for predictive analytics in donor recruitment, plasma yield optimization, and adverse event monitoring.

Growth Prospects of the Plasma Derived Therapy Market

The growth of the plasma derived therapy market is driven by both demand-side and supply-side factors. On the demand side, rising diagnosis rates for rare diseases and broader treatment availability are key factors. On the supply side, the expansion of plasma collection centers and technological improvements are supporting a more efficient and scalable supply chain.

Government initiatives, such as the U.S. Plasma Protein Therapeutics Association's (PPTA) push for increased donations, and WHO's efforts to improve access to life-saving biologics in emerging economies, are major growth stimulants.

Additionally, as healthcare providers continue to integrate these therapies into standard treatment protocols for immunological and hematological conditions, the market's base will significantly expand.

Opportunities and Challenges in the Plasma Derived Therapy Market

Opportunities

Expansion in emerging markets: With underdiagnosed populations and unmet medical needs, countries in Latin America, Africa, and Southeast Asia present vast opportunities for growth.

Strategic collaborations and acquisitions: Pharma giants are collaborating to pool resources for plasma collection, R&D, and manufacturing scale-up.

Innovation in plasma fractionation: Continued research into improving fractionation techniques and minimizing wastage offers scope for cost-effective production.

Personalized plasma therapies: As precision medicine evolves, there's potential for tailoring plasma products to specific patient profiles, enhancing outcomes.

Challenges

Donor availability: Sustained supply depends heavily on voluntary donors; disruptions due to pandemics or logistics can severely affect supply chains.

Pricing pressures: With growing demand comes scrutiny from governments and insurers to keep therapy prices in check.

Regulatory complexity: Navigating multi-country regulations for donor safety, product approval, and quality assurance is time-consuming and expensive.

Cold chain dependency: Plasma products require stringent storage and transportation conditions, especially in lower-income regions lacking reliable logistics.

Recent Developments in the Plasma Derived Therapy Market

CSL Behring recently announced a multi-million-dollar expansion of its plasma collection network across the U.S. and Europe.

Takeda Pharmaceutical Company received approval for a new intravenous immunoglobulin (IVIG) therapy targeting chronic inflammatory demyelinating polyneuropathy (CIDP).

Octapharma launched a clinical study focused on plasma-derived fibrinogen concentrate to treat postpartum hemorrhage.

Grifols completed the construction of one of the world's largest plasma fractionation plants in North Carolina, enhancing its global supply capabilities.

ADMA Biologics expanded its FDA-approved plasma collection centers to meet increasing demand for immune globulin products.

These developments highlight the fast-paced innovations and strategic investments shaping the future of this market.

Market Growth Outlook and Projections

Between 2025 and 2034, the market is expected to nearly double, underlining strong investor and commercial interest in this biologics sub-segment. The CAGR of 6.90% is supported by:

Greater diagnostic capabilities

Enhanced access in emerging economies

Scalable plasma collection and manufacturing infrastructure

Rising global disease burden for immune and hematologic conditions

Biopharmaceutical companies are expected to invest heavily in decentralized donation platforms, AI-based donor screening, and real-time logistics management to improve reach and efficiency.

Competitive Landscape and Key Player Insights

The plasma derived therapy market is moderately consolidated with global leaders dominating key segments such as immunoglobulins, clotting factors, and albumin.

CSL Behring

One of the largest players globally, CSL Behring has a broad portfolio covering immunodeficiencies, bleeding disorders, and critical care. Its investments in R&D and plasma center expansion keep it at the forefront of innovation.

Takeda Pharmaceutical Company Limited

Takeda holds a strong position in rare disease therapeutics, with extensive plasma-derived products including Albumin and IVIG. Its global footprint supports a diverse product distribution strategy.

BPL (Bio Products Laboratory)

UK-based BPL focuses on therapeutic proteins derived from human plasma and continues to grow its export base and clinical pipeline.

ADMA Biologics

ADMA specializes in immunoglobulin products and has received multiple FDA approvals for IVIG products targeting infectious and immune diseases.

Biotest AG

Biotest is known for its expertise in immunology and hematology, offering a comprehensive plasma-derived product line used in hospital and outpatient settings.

Octapharma

Headquartered in Switzerland, Octapharma operates globally with an emphasis on hematology, immunotherapy, and intensive care plasma solutions.

Grifols

As a vertically integrated company, Grifols controls the plasma therapy lifecycle-from donation to product distribution-allowing greater flexibility and responsiveness to market demands.

Kamada Pharmaceuticals

Focused on specialty plasma-derived products, Kamada develops treatments for rare and orphan diseases, with an emphasis on respiratory and immune indications.

SK Plasma

Based in South Korea, SK Plasma supplies domestic and international markets, with major investments in fractionation technology and research.

Kedrion

An Italian biotech firm, Kedrion provides plasma derivatives for genetic and acquired disorders. It is known for its ethical donation programs and global humanitarian efforts.

Frequently Asked Questions (FAQs)

What was the value of the global plasma derived therapy market in 2024?
The market was valued at USD 24.00 billion in 2024.

What is the forecasted value of the market by 2034?
It is expected to reach USD 46.77 billion by 2034.

What is driving growth in the plasma therapy market?
Growth is driven by increasing healthcare access, a higher burden of immune-related and bleeding disorders, and global expansion of plasma donation infrastructure.

Which region dominates the market?
North America holds the largest share, followed by Europe and rapidly growing Asia-Pacific.

Who are the key players in the market?
Major players include CSL Behring, Takeda, Octapharma, Grifols, ADMA Biologics, Biotest AG, Kamada Pharmaceuticals, SK Plasma, Kedrion, and BPL.

What are the primary challenges faced by the market?
Challenges include limited plasma supply, high production costs, regulatory complexities, and logistics hurdles.

How is technology influencing this market?
AI, blockchain, and advanced fractionation techniques are improving operational efficiency, donor targeting, and quality assurance.

The plasma derived therapy market stands at a critical juncture of growth, technological innovation, and increasing patient demand. With its ability to provide life-saving treatments for rare and chronic diseases, plasma-based therapy is no longer a niche segment but a cornerstone of modern healthcare. As the market moves toward USD 46.77 billion by 2034, stakeholders will need to navigate challenges related to plasma supply, cost structures, and global access, while leveraging innovation and collaboration to deliver safe, effective therapies worldwide.

For detailed insights, forecasts, and strategic recommendations, access the full market report by Expert Market Research.

Find More Blog:

Seizures Drug Pipeline Analysis: https://rb.gy/jm0vdv

Wilson Disease Drug Pipeline Analysis: https://rb.gy/6uoaoy

Sinusitis Drug Pipeline Analysis: https://rb.gy/wzi7my

Post-Traumatic Stress Disorder (PTSD) Drug Pipeline Analysis: https://rb.gy/24kjl0

Psoriatic Arthritis Drug Pipeline Analysis: https://rb.gy/01d7e8

Media Contact:

Company Name: Claight Corporation
Contact Person: Deepanshu Choudhary, Digital Marketing
Email: sales@expertmarketresearch.com
Toll Free Number: US +1-415-325-5166 | UK +44-702-402-5790
Address: 30 North Gould Street, Sheridan, WY 82801, USA
Website: www.expertmarketresearch.com

About Us:

Expert Market Research is a leading market research firm delivering data-driven insights to the pharmaceutical, biotechnology, and medical device industries. Our comprehensive research solutions include market research reports, providing in-depth analysis of industry trends and competitive landscapes; drug pipeline reports, tracking drug development progress, clinical trials, and regulatory approvals; epidemiology reports, offering detailed disease prevalence and patient population studies; and patent reports, assessing intellectual property landscapes and innovation trends, among others. Leveraging proprietary data, advanced analytics, and expert methodologies, we help businesses navigate complex markets, optimize strategies, and drive innovation. We empower clients with actionable intelligence, enabling them to make informed decisions and stay ahead in the rapidly evolving healthcare sector.

This release was published on openPR.